SCHEMBL23110367

SCHEMBL23110367

N#Cc1cc(N2CCCCC2)nc2cc(Cl)ccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.52
HTT P42858 1/20 0.52
ATM Q13315 1/20 0.52
HSD17B10 Q99714 4/20 0.52
KDM4E B2RXH2 3/20 0.52
PKM P14618 2/20 0.52
CHKA P35790 1/20 0.47
CNR1 P21554 2/20 0.46
CNR2 P34972 2/20 0.46
ALOX15 P16050 2/20 0.45
CASP1 P29466 2/20 0.45
ACHE P22303 2/20 0.43
AR P10275 1/20 0.42
CYP3A4 P08684 1/20 0.42
DPP4 P27487 1/20 0.42
HTR3E A5X5Y0 1/20 0.42
HTR3B O95264 1/20 0.42
HTR3A P46098 1/20 0.42
HTR3D Q70Z44 1/20 0.42
HTR3C Q8WXA8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23110352 0.89 L3MBTL1 (0.52) L3MBTL1HTTATMHSD17B10KDM4E
SCHEMBL23110353 0.88 L3MBTL1 (0.53) L3MBTL1HTTATMHSD17B10KDM4E
SCHEMBL23110385 0.85 HTT (0.48) L3MBTL1HTTATMHSD17B10KDM4E
SCHEMBL30762511 0.80 L3MBTL1 (0.77) L3MBTL1HTTATMHSD17B10KDM4E
SCHEMBL23110363 0.79 L3MBTL1 (0.44) L3MBTL1HTTATMHSD17B10KDM4E
SCHEMBL6508977 0.79 KDM4E (0.78) L3MBTL1HSD17B10KDM4EPKMCHKA
SCHEMBL3863778 0.79 KDM4E (0.78) L3MBTL1HSD17B10KDM4EPKMCHKA
SCHEMBL6511143 0.79 KDM4E (0.78) L3MBTL1HSD17B10KDM4EPKMCHKA
SCHEMBL23110067 0.77 L3MBTL1 (0.45) L3MBTL1HTTATMHSD17B10KDM4E
SCHEMBL23110434 0.76 HRH4 (0.58) L3MBTL1HTTATMHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220315568-A1 INHIBITORS OF SARM1 DISARM THERAPEUTICS, INC. 2022-10-06 US disclosed
WO-2021050913-A1 INHIBITORS OF SARM1 DISARM THERAPEUTICS, INC. (US) 2021-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315568-A1 INHIBITORS OF SARM1 SARM1, SMN1; SMN2, SARNP L3MBTL1 186/4885HTT 923/4885ATM 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.